Director — Michael Grissinger: The filing discloses the appointment of a sitting director to a board committee, which is a routine administrative change rather than a departure or executive hire.

Results of Operations and Financial Condition. On August 4, 2026, the Company issued a press release announcing financial and operational results for the quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…

Director — Michael Grissinger: Appointment of Michael Grissinger as a director with an initial stock option grant and annual retainer.

The filing pertains to an amendment of the stock and incentive plan, not a management change.

Results of Operations and Financial Condition. On May 7, 2026, the Company issued a press release announcing financial and operational results for the quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…

Chairman of the Board and Lead Independent Director — Spyros Papapetropoulos: Dr. Papapetropoulos resigned due to competing professional commitments and evolving board dynamics arising from differing views on the Company’s strategic direction.

Results of Operations and Financial Condition. On March 10, 2026, the Company issued a press release announcing financial and operational results for the year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha…

Other Events. On April 26, 2024, Lipocine Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners as sales agent (the “Sales Agent”) to offer and sell shares of its common stock, par value $0.0001 per share (“Common Stock”), from time to time through the Sales Agent. On February 26, 2026, the Company filed a prospectus supplement under the Sales Agreement for an aggregate of $50,000,000 of shares of Common Stock to be sold under the Sal…

Results of Operations and Financial Condition. As of January 31, 2026, Lipocine Inc. (the “Company”) had approximately $19 million of cash and cash equivalents. The foregoing estimate is preliminary and unaudited and reflects the Company’s preliminary estimates with respect to its cash at January 31, 2026, based on currently available information and is subject to completion of financial closing procedures. This estimate should not be viewed as a substitute for the Company’s annual financial…

Director — Jeffrey Fink: Jeffrey Fink resigned from the Board for personal reasons.

Results of Operations and Financial Condition. On November 6, 2025, the Company issued a press release announcing financial and operational results for the quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…

Results of Operations and Financial Condition. On August 5, 2025, the Company issued a press release announcing financial and operational results for the quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…

Entry into a Material Definitive Agreement. On November 12, 2015, the Board of Directors of Lipocine Inc. (the “Company”) adopted a stockholder rights plan. The plan is similar to plans adopted by many other companies and was not adopted in response to any hostile takeover attempt. On November 5, 2018, the Board of Directors adopted an Amended and Restated Stockholder Rights Agreement in order to extend the expiration date of the stockholder rights plan until November 5, 2021. On November 1,…

Material Modification to Rights of Security Holders. The information included in

The filing discloses the approval of a cash bonus plan for executive officers, which is a compensatory arrangement rather than a change in management personnel.

Entry into a Material Definitive Agreement. On April 26, 2024, Lipocine Inc. (the “Company”), entered into a sales agreement (the “ATM Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.0001 per share (the “Shares”), from time to time, in an at-the-market public offering. The Company will offer and sell up to $10,616,169 of Shares for sale under the ATM Agreement, pursuant to the Re…

Termination of a Material Definitive Agreement. On April 24, 2024, the Company provided notice to Cantor Fitzgerald & Co. (“Cantor”) of its election to terminate the Controlled Equity Offering SM Sales Agreement between them dated March 6, 2017 (the “Sales Agreement”). Under the Sales Agreement, the Company could sell from time to time, at its option, shares of common stock by any method that was deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act. C…

Results of Operations and Financial Condition On March 7, 2024, the Company issued a press release announcing financial and operational results for the year ended December 31, 2023. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.